73 results about "Biofilm inhibition" patented technology

There is provided a method of inhibiting the development of a biofilm adjacent a surface, the method comprising intermittently applying a biofilm inhibiting substance to a collection of microorganisms having biofilm developing potential. There is also provided a method of inhibiting the development of a biofilm adjacent a surface, the method comprising inhibiting the biofilm developing potential of a collection of microorganisms without completely eradicating said collection of microorganisms. Also provided are a system for inhibiting the development of a biofilm, and a method and system for inhibiting the production of an enzyme by a collection of microorganisms.

There is provided a method of inhibiting the development of a biofilm adjacent a surface, the method comprising intermittently applying a biofilm inhibiting substance to a collection of microorganisms having biofilm developing potential. Other embodiments are also described.

Substrates with a biofilm-inhibiting coating comprising an inorganic condensate modified with organic groups, at least some of the organic groups of the condensate containing fluorine atoms and the coating comprising copper colloids or silver colloids.

Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed.

Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of Pseudomonas and more particularly P. aeruginosa.

A method comprises preventing or inhibiting bacterial adhesion and / or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.

The present invention provides a new amide compound and salt thereof that is capable of inhibiting biofilm formation or removing deposited biofilms. The present invention also provides a biofilm formation inhibitor or a biofilm remover containing the amide compound or salt thereof as an active ingredient.An amide compound or salt thereof according to the present invention is denoted by General Formula (1):wherein R1 is a hydrogen atom or a hydroxyl group, R2 is a C5-12 alkyl group, and Q is a substituent denoted by Formula (Q1) or (Q2),wherein n and m are 0 or 1.

The penetration of moisture and dirt often leads to a premature failure of electroacoustic miniature transducers that are used in hearing aids. A transducer membrane of a miniature transducer is provided at least in part with a hydrophobic and / or oliophobic and / or biofilm-inhibiting coating that, because its layer thickness is less than 10 μm, does not significantly influence the acoustic characteristic of the miniature transducer, and that prevents degradation of the transmission characteristic due to moisture, or moisture-caused damage to the miniature transducer. In addition, the adherence of dirt particles is prevented.

Botanical extracts and derivative compositions are described for activating or inhibiting the formation and development of bacterial biofilms. Gymnemic acids and other associated saponins are isolated from botanical extractions of the Gymnema sylvestre plant and are used to modulate bacterial biofilm virulence, especially biofilms associated with Staphylococcus aureus. Gurmarin, a polypeptide isolated from botanical extractions of the Gymnema sylvestre plant are used to inhibit biofilm formation, especially biofilms associated with Staphylococcus aureus. Methods for isolating gurmarin (as well as other peptides from botanical extracts) are described using isoelectric focusing separation techniques. Various uses for both research and health care concerns are described for the biofilm activators (modulators) and for the biofilm inhibitor.

A method of enhancing the growth of an anima, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.

A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.

The invention relates to a micro-fluidic chip and detection method for screening a bacterial biofilm inhibitor. The chip consists of substrates for integrating a micro array electrode and a cover plate comprising micro channels, and specifically comprises functional units including sample introducing channels, fluorescent reagent sample introducing channels, biofilm culturing regions, biofilm andmedicine interaction regions, biofilm fluorescent observation regions and the like. Through the adoption of the micro-fluidic chip disclosed by the invention, multiple functions of bacterial biofilm culturing, biofilm fluorescent observation, biofilm impedance monitoring and the like can be realized, the micro-fluidic chip can be applied to biofilm formation process observation and monitoring, medicine and biofilm interaction process on-line in-situ monitoring, bacterial biofilm inhibitor screening and the like; and the multi-functional chip has the advantage of detecting the changes of the biofilm in an in-situ nondestructive real-time online manner, and can analyze the action situation of different medicines on different bacterial biofilms, and then the high-efficiency screening of the biofilm inhibitor is realized.

The application relates to oral care compositions comprising substantive polyesteramides formed from polyols, polycarboxylic acids (or esters, anhydrides or halides thereof) and arginine. The formed polyesteramides are active in biofilm inhibition, biofilm dissolution and retarding or preventing acid production from oral bacteria.

The present disclosure describes a process for the use of peracid compositions to eliminate and / or control the growth of undesirable bacteria, including contaminating bacteria, in water systems is disclosed. Beneficially, the peracid compositions and methods of use of the same are effective in reducing or eliminating both planktonic and sessile bacterial contamination.

Streptococcus mutans is the most important pathogenic bacteria causing dental caries. When streptococcus mutans is adhered to the surfaces of teeth in a biofilm form, a dental plaque biofilm can be formed. Due to the film forming effect of dental plaque microorganisms, dental plaque bacteria generate drug resistance to antibiotics or bactericides, and the effect of preventing and treating decayed teeth and periodontal diseases is reduced. The invention discloses a composition capable of inhibiting streptococcus mutans biofilm formation. According to the composition, a biological membrane inhibitor and sodium fluoride are combined for use, and formation of a biological membrane is reduced by interfering quorum sensing, so that bacterial drug resistance is reduced, and the efficiency of sodium fluoride is improved.

The invention belongs to the medical field and discloses benzothiazole compounds as well as a preparation method and an application thereof. The benzothiazole compounds have the structural formula shown in formula I, wherein Ar is substituted benzene ring five-member nitrogen heterocyclic ring, six-member nitrogen heterocyclic ring, indolyl or substituted indole group; R is -H,-F, -Br, -NO2, -NH2,-N(CH3)2, 4-methylpiperazine-1-yl, 4-morpholinyl, -OH or -OCH3. 2-methyl benzothiazole is used as a lead compound and modified and transformed, a series of benzothiazole compounds are designed and synthesized, the obtained compounds have better bacterial signal molecule c-di-GMP aggregation induction activity, smaller toxic and side effects and higher safety and can be applied to preparation of bacterial biofilm inhibitors, particularly pseudomonas aeruginosa biofilm inhibitors, when Ar is 3-position substituted indole, the induction activity is obviously superior to a positive control compound.

The formation and maintenance of microbial biofilms is shown to be dependent on signaling pathways mediated by cyclic di-GMP. In the absence of such signaling, microbes detach from a biofilm, and thereby become more readily treatable with conventional antibiotics. Chemical or biological means that interfere with cyclic-di-GMP signaling induce biofilm dissolution, providing for a new class of antibiotics. In one embodiment of the invention, the biofilm inhibitor is an analog of cyclic-di-GMP, which competitively or non-competitively blocks signaling. In another embodiment of the invention, the biofilm inhibitor is a genetic sequence that interferes with cyclic-di-GMP synthesis or signaling.

The invention relates to a novel sustainable sustained-release method for a biofilm inhibiting molecule D-amino acid. The method comprises the following steps: sulfuric acid-modified halloysite nanotubes are adopted to load a D-amino acid, then cationic and anionic weak polyelectrolytes having pH response characteristics are assembled on the surface of the modified halloysite layer by layer, and therefore the halloysite composite carrier material with pH response characteristics is prepared. According to the method provided by the invention, the composite carrier material prepared by the method effectively improves a utilization ratio of the D-amino acid by sustained release, at the same time, the composite carrier has the reloading ability to the D-amino acid by adjust and control of thepH of the solution, so that the sustainable sustained-release utilization of the biofilm inhibiting molecule D-amino acid is realized, and a novel strategy for long-term control of biofilm contamination is provided.

A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.

The invention discloses a biological film inhibiting peptide and application thereof. The amino acid sequence of the biological film inhibiting peptide is as shown in SEQ ID NO.1. The biological film inhibiting peptide disclosed by the invention is simple in preparation method, can be synthesized through a conventional solid-phase synthesis method, is capable of inhibiting the formation and surface adhesion of a staphylococcus epidermidis biological film after being purified, can be jointly applied to inhibit drug-resistant staphylococcus epidermidis with other antibacterial drugs, and has great significance on clinically treating staphylococcus epidermidis infection.

Anti-infective and biofilm-inhibiting activities of aryl isoquinoline-derivatives of the general formulae 1 to 3are described.

In the case of a voltage source with a housing for supplying power to a medical device which can be worn on or in the human body, the failure rate determined by external environment influences or contamination is to be reduced. To this end, provision is made for the exterior of the housing of the voltage source to be provided with a hydrophobic and / or oleophobic and / or biofilm-inhibiting coating. The moisture and contamination-repellent coating largely protects the voltage source from external environmental influences and contamination. Failures determined by external environmental influences or contamination are herewith largely avoided.

Disclosed are carrier compositions for local administration of one or more active pharmaceutical ingredients to a subject in need of treatment. The carrier compositions comprise an in situ gelling agent comprising a poloxamer, particularly, an in situ gelling agent comprising Poloxamer 407, a biofilm inhibiting agent and a mucosal lubricant. Further disclosed are pharmaceutical compositions comprising the carrier composition and uses thereof for the treatment of chronic rhinosinutitus.

The present invention relates to substituted 5-aryl-2-aminoimidiazole compounds being active against microbial biofilm formation. The invention also relates to compositions comprising a microbial biofilm inhibiting amount of said substituted 5-aryl-2-aminoimidiazole compounds in combination with excipients. Methods for inhibiting or controlling microbial biofilm formation in a plant, a body part of a human or an animal, or a surface with which a human or an animal may come into contact are also disclosed.

The invention discloses application of a houttuyfonate analogue in preparation of a streptococcus mutans growth and biological membrane inhibitor. The preparation method of the inhibitor comprises the following steps: 1, dissolving sodium new houttuyfonate in a dimethyl sulfoxide solvent having the concentration of 5 percent to obtain an inhibitor mother solution with the sodium new houttuyfonate concentration of 10 mg / mL; 2, carrying out gradient dilution on the mother solution obtained in the step 1 by using dimethyl sulfoxide having the concentration of 5 percent; and adding the inhibitor into a liquid culture medium, wherein the concentration of the inhibitor is 50-100 [mu]g / mL, and the final concentration of the dimethyl sulfoxide is 0.5% (v / v). The inhibitor can inhibit streptococcus mutans growth and biofilm formation, has the advantages of small molecular weight, simple structure, stable property, good biocompatibility and the like, can remarkably inhibit main pathogenic bacteria of caries, and has the potential of serving as anti-caries drugs.

Silicone elastomers exhibiting non-transitory biofilm inhibiting properties are prepared from crosslinkable components which include an organopolysiloxane bearing at least one silicon-bonded hydrogen and / or at least one alkenyl group, and at least one carboxylic acid, carboxylic acid ester, or carboxylic acid anhydride group, which becomes covalently bonded to the polymer before or during curing.